Cordance Medical
Mountain View, US · Founded 2018 · 14 employees on LinkedIn · 6 known investors
Cordance Medical is developing NeuroAccess, a non-invasive medical device that uses low-frequency focused ultrasound and microbubbles to reversibly open the blood-brain barrier at targeted sites, enabling drug delivery and blood-based biomarker measurement. It targets brain diseases including brain cancers, Alzheimer's, Parkinson's, and epilepsy, and its device received the FDA's Breakthrough Device Designation.
Founders & leadership
RD
Ryan DittamoreCEO
Investors · 6
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2021 | $998.5K |
| National Science Foundation | Phase I | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cordance Medical do?
- Cordance Medical is developing NeuroAccess, a non-invasive medical device that uses low-frequency focused ultrasound and microbubbles to reversibly open the blood-brain barrier at targeted sites, enabling drug delivery and blood-based biomarker measurement. It targets brain diseases including brain cancers, Alzheimer's, Parkinson's, and epilepsy, and its device received the FDA's Breakthrough Device Designation.
- Who are Cordance Medical's investors?
- Cordance Medical's investors include Angel Physicians Fund, Beresford Ventures, Creative Destruction Lab (CDL), Shanda Group, SmartGateVC, Sonder Capital.
- Where is Cordance Medical headquartered?
- Cordance Medical is headquartered in Mountain View, US.